Ocuphire Pharma has dosed the first participants in the VEGA-3 phase 3 clinical trial investigating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia, according to a press release.
The randomized, double-masked, placebo-controlled, multicenter trial will investigate the efficacy and safety of phentolamine ophthalmic solution as a “noninvasive, convenient alternative to traditional corrective measures” for presbyopia in 545 participants. They will be randomly assigned 3:2 to receive phentolamine ophthalmic solution or placebo each evening, with follow-up for 48